Andrew Feigin, AD/PD 2021: Results from the Phase 2 SIGNAL Trial

touchNEUROLOGY coverage at CONy 2024 CONy President, Prof. Amos D. Korczyn, a distinguished figure in the field of neurology, shares an update on the 18th World Congress on Controversies in Neurology congress, held in the city of London, UK, brought together leading experts to debate and discuss the most contentious issues within neurology. Prof. Korczyn, […]

The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the key results, their significance and the next steps. The abstract entitled […]

ANX005, a humanized monoclonal antibody, is designed to inhibit the classical complement pathway which has been associated with Huntington’s disease (HD). In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) to discuss the role of complement activation in people living with HD and why ANX005 is […]